Mangoceuticals (MGRX) Return on Capital Employed (2023 - 2026)

Mangoceuticals has disclosed Return on Capital Employed across 4 years of filings, most recently posting 17.95% for Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 17.95%, up 572.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 17.95% (up 572.0% YoY), and the FY2025 annual result was 29.21%, down 226.0% from the prior year.
• Return on Capital Employed came in at 17.95% for Q1 2026 at Mangoceuticals, up from 26.32% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 1683.96% in Q1 2024 to a low of 828.98% in Q4 2023.
• The 4-year median for Return on Capital Employed is 31.28% (2025), against an average of 46.08%.
• Across the five-year window, Return on Capital Employed surged 81559 bps in 2024 and slumped 170762 bps in 2025, its largest moves.
• Mangoceuticals' Return on Capital Employed stood at 828.98% in 2023, then soared by 98 bps to 13.39% in 2024, then plunged by 97 bps to 26.32% in 2025, then surged by 32 bps to 17.95% in 2026.
• The last three Return on Capital Employed figures came in at 17.95% (Q1 2026), 26.32% (Q4 2025), and 72.26% (Q3 2025), per Business Quant data.